Abstract
Background
Hemangioblastomas of the central nervous system are a prominent feature of von Hippel-Lindau-disease (vHL). Hemangioblastomas are known to secrete vascular endothelial growth factor (VEGF), suggesting a potential role of VEGF as a biomarker for tumor growth.
Methods
Plasma VEGF samples from 24 patients with von Hippel-Lindau disease were analyzed by solid-phase proximity ligation assay (PLA). Levels were monitored over time together with numeric and volumetric CNS tumor burden, and compared to plasma VEGF levels in healthy controls.
Results
The mean yearly progression in tumor volume was 65.5%. Yearly risk of developing one or several new CNS tumor(s) was 50%. No significant correlation between tumor burden and levels of VEGF was seen. VEGF levels in patients (31.55–92.04; mean 55.83, median 56.41) as measured by immunodetection in a solid-phase PLA did not differ significantly from controls (37.38–104.56; mean 58.89, median 54.12) (p = 0,266).
Conclusion
The increase in total CNS tumor volume in vHL occurred in a saltatory manner. The risk of developing a new lesion was 50% per year. We found no evidence for VEGF secretion from CNS hemangioblastomas in vHL in circulating blood. Other potential biomarkers should be explored to assess progression of tumor burden in vHL.
Publisher
Public Library of Science (PLoS)
Reference27 articles.
1. von Hippel-Lindau disease;RR Lonser;Lancet,2003
2. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease;JE Wanebo;J Neurosurg,2003
3. Genetics of Von Hippel-Lindau Disease;DC Dwyer;AJNR Am J Neuroradiol,2017
4. A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease;SK Flores;J Clin Endocrinol Metab,2019
5. Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein;G Minervini;Sci Rep,2015